Protagonist Therapeutics Inc (PTGX)

Feb 21, 2025, 7:00 AM EST - 2 days ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jan 13, 2025, 5:55 AM EST - 5 weeks ago

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 6, 2025, 4:05 PM EST - 6 weeks ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Dec 19, 2024, 4:05 PM EST - 2 months ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Nov 22, 2024, 7:30 AM EST - 3 months ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 19, 2024, 7:30 AM EST - 3 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Nov 7, 2024, 4:05 PM EST - 3 months ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 4:05 PM EST - 3 months ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Sep 10, 2024, 1:17 PM EDT - 5 months ago

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Sep 3, 2024, 7:30 AM EDT - 6 months ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 7:00 AM EDT - 7 months ago

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 31, 2024, 9:15 AM EDT - 7 months ago

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Jul 22, 2024, 7:00 AM EDT - 7 months ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

May 31, 2024, 7:30 AM EDT - 9 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

May 14, 2024, 4:05 PM EDT - 10 months ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

May 7, 2024, 4:10 PM EDT - 10 months ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

May 7, 2024, 4:05 PM EDT - 10 months ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:00 AM EDT - 11 months ago

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Mar 6, 2024, 4:05 PM EST - 1 year ago

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Feb 27, 2024, 4:05 PM EST - 1 year ago

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 21, 2024, 5:00 PM EST - 1 year ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Feb 7, 2024, 5:00 PM EST - 1 year ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Jan 31, 2024, 4:05 PM EST - 1 year ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

TAK

Jan 29, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Jan 3, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 7:30 AM EST - 1 year ago

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Dec 8, 2023, 1:03 AM EST - 1 year ago

Protagonist Therapeutics: On A Ship That Could Be About To Sail

Nov 9, 2023, 3:55 PM EST - 1 year ago

Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting

Oct 30, 2023, 4:05 PM EDT - 1 year ago

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

Oct 9, 2023, 7:00 AM EDT - 1 year ago

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

Oct 3, 2023, 4:05 PM EDT - 1 year ago

Protagonist Therapeutics Reports Granting of Inducement Award

Sep 22, 2023, 3:35 PM EDT - 1 year ago

Protagonist Therapeutics: There Are Reasons Behind Johnson & Johnson's Optimism

Sep 5, 2023, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics to Present at Upcoming Investor Conferences

Sep 4, 2023, 2:56 AM EDT - 1 year ago

Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV

Aug 9, 2023, 2:44 PM EDT - 1 year ago

Protagonist: Rusfertide Has Potential For Patients With Polycythemia Vera

Aug 9, 2023, 7:00 AM EDT - 1 year ago

Protagonist Receives $34 Million from Warrant Exercises

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 27, 2023, 7:46 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

BCLI COSM SHCR XAIR

Jul 4, 2023, 3:30 AM EDT - 1 year ago

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Jun 9, 2023, 8:05 AM EDT - 1 year ago

Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Ru

Jun 6, 2023, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress

Jun 1, 2023, 4:01 PM EDT - 1 year ago

Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

May 25, 2023, 5:18 PM EDT - 1 year ago

Protagonist Therapeutics Sees Steady If Bumpy Progress

May 24, 2023, 5:33 PM EDT - 1 year ago

Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023

May 12, 2023, 7:00 AM EDT - 1 year ago

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

May 11, 2023, 4:05 PM EDT - 1 year ago

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

May 11, 2023, 10:17 AM EDT - 1 year ago

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association